41 results about "Hidradenitis" patented technology

The invention relates to a traditional Chinese medicine for treating hidradenitis suppurativa. The traditional Chinese medicine is prepared from the following medicinal materials in parts by weight: 15 parts of mucuna paohwashanica, 14 parts of ficus hispida L. f., 14 parts of colocasia antiquorum schott, 10 parts of begonia palmata, 12 parts of celastrus angulata maxim, 12 parts of crotalaria albida heyne, 12 parts of rabdosia, 12 parts of white gentian, 14 parts of anemone rivularis buch, 15 parts of oxalis rubra, 8 parts of piper wallichii, 15 parts of hypericum uralum, 12 parts of claoxylon polot merr, 10 parts of anemome tomentosa, 10 parts of Ixeris polycephala, 5 parts of peltate yam rhizome, 8 parts of stichopus japonicus, 10 parts of excoecaria venenata and 10 parts of rubus irenaeus focke. The clinical trial proves that the traditional Chinese medicine can safely and effectively treat hidradenitis suppurativa.

The invention discloses an externally applied traditional Chinese medicine powder for diminishing inflammation and swelling, which is prepared from the following raw material medicines by weight percentage: 20-30% of realgar, 25-35% of rhubarb, 10-20% of turmeric, 10-20% of cortex phellodendri, and 10-20% of bulbus fritillariae thunbergii. The externally applied powder for diminishing swelling isprepared by the compatibility of only five raw material medicines, has the efficacies of promoting blood circulation and removing blood stasis, diminishing swelling and relieving pain, expelling stasis and stagnation, and promoting pus discharge and tissue regeneration. The externally applied traditional Chinese medicine powder is simple in compatibility, distinct in treatment effect, and short in course of treatment, and does not have toxic or side effect. The externally applied powder for diminishing swelling can treat acute and chronic lobular hyperplasia of mammary glands, lymphnoditis, mumps, traumatic injuries, lipoma, furuncle, pustule of finger tip, paronychia, tinea unguium, external piles, anus abscess and hemangioma, with wide treatment range and low cost, and also can be used for treating mammary gland disease and foot-and-mouth disease of cows, with very good treatment effect.

This invention relates to compositions and methods of treatment of skin or mucosal disorders by administration of compositions comprising at least one EGFR inhibitor, such as topical compositions comprising erlotinib. The compositions of this invention are useful for the treatment, prevention or amelioration of skin or mucosal disorders like psoriasis, palmoplantar psoriasis, acquired palmoplantar keratosis, eczema, ichtyosis vulgaris, non-melanoma skin cancer, actinic keratosis, a keratinization skin disorder, a keratinization mucosal disorder, pachyonychia congenita, hidradenitis suppurativa, Gorlin syndrome, prurigo nodularis and prurigo pigmentosa.

The present invention discloses one kind of Chinese herbal medicine digestant for treating lymphoid tuberculosis and lymphadenitis, and the Chinese herbal medicine digestant is prepared with asparagus 6-10 weight portions, burrerfly bush flower 9-12 weight portions, Chinese sumac 10-15 weight portions, dandelion 2-4 weight portions, mullein nightbrier leaf 1-2 weight portions, and Chinese honeylocust spine 1-3 weight portions. It is used in treating lymphoid tuberculosis and lymphadenitis, and has high curative effect and no toxic side effect.

A novel polypeptide, and an antibacterial agent, antifungal agent and / or antiseptic containing as an effective ingredient the polypeptide are disclosed. The polypeptide of this invention has an amino acid sequence shown in SEQ ID NOs:1 to 12 and 13 to 31. This antibacterial agent, antifungal agent and / or antiseptic is useful for the prevention, amelioration or treatment of diseases such as burn, decubitus, wound, skin ulcer, leg ulcer, diabetic ulcer, occlusive arterial disease and arteriosclerosis obliterans, cellulitis, acute lymphangitis, lymphadenitis, erysipelas, skin abscess, necrotizing subcutaneous infection, staphylococcal scalded skin syndrome (SSSS), folliculitis, facial furuncle, suppurative hidradenitis, carbuncle, infectious paronychia, erythrasma and severe infection (sepsis).

Compositions and related methods of treating diseases of the pilosebaceous unit including acne, rosacea and hidradenitis. Through the introduction of active ingredients including xylitol and farnesol at a treatment location, biofilms associated with acne, roasacea and hidradenitis are disrupted and / or inhibited. The composition can be in the form of a topical medication or cream including a pharmaceutically acceptable carrier and the active ingredients. The composition can further comprise beneficial skin supplements to further enhance the treatment effects. The composition can be utilized in conjunction with additional biofilm disruption treatments.

The present disclosure relates to methods for treating Hidradenitis Suppurativa using a LTA4H inhibitor. Also disclosed herein are the LTA4H inhibitors, for treating Hidradenitis Suppurativa patients, as well as medicaments, dosing regimens, pharmaceutical formulations, combinations, dosage forms, and kits for use in the disclosed uses and methods.

The present invention pertains generally to the field of therapeutic compounds. More specifically the present invention pertains to certain substituted 1-methyl-4-[(4-phenylphenyl)sulfonylmethyl]cyclohexanol and 1-methyl-4-[[4-(2-pyridyl)phenyl]sulfonylmethyl]cyclohexanol compounds (collectively referred to herein as CHMSA compounds) that are useful, for example, in the treatment of disorders (e.g., diseases) including, e.g., multiple myeloma, diffuse large B-cell lymphoma, acute myeloid leukemia, eosinophilic leukemia, glioblastoma, melanoma, ovarian cancer, chemotherapy resistant cancer, radiation resistant cancer, inflammatory arthritis, rheumatoid arthritis, psoriatic arthritis, psoriasis, ulcerative colitis, Crohn's disease, systemic lupus erythematosus (SLE), lupus nephritis, asthma, chronic obstructive pulmonary disease (COPD), non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), autoimmune hepatitis, hidradenitis suppurativa, etc. The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, for example, in therapy.

This invention relates to Ligulatrovine A separated from Ligularia actroviolacea that can prevent and treat diseases related to Staphylococcus aureus and beta hemolytic streptococcus, its pharmaceutical salts and drug composition. Ligulatrovine A has significant inhibitive effect on Gram-positive bacteria, and can prevent and treat diseases such as boil, pustule, pneumonia, osteomyelitis, acute myocarditis, endocarditis, meningitis, mastitis, cystitis, pelvic inflammation, urinary inflammation, prostatitis, bacteremia, or abscess in muscle, skin, urogential region or central nervous system caused by Gram-positive bacteria infection.

Compositions and methods for treating skin conditions, ailments or diseases, such as autoinflammatory skin diseases such as psoriasis, dermatitis, pyoderma gangrenosum, palmoplantar pustulosis, prurigo nodularis and / or hidradenitis suppurativa, are described. The compositions comprise an agent that modulates the aryl hydrocarbon receptor, in particular an agent that agonizes the receptor. In one embodiment, the agent is indigo or a derivative of indigo, such as indirubin.

The invention relates to the technical field of traditional Chinese medicine and particularly discloses a traditional Chinese medicine for treating neck chronic lymphadenitis of children. The traditional Chinese medicine comprises the following components in parts by weight: 10-15 parts of rheum officinale, 4-6 parts of burdocks, 2-3 parts of pangolin, 1 part of borneol, 1 part of scorpio, 1 part of radix angelicae and 0.5 part of indigo naturalis. In the formula, rheum officinale and burdocks which are monarch drugs are mainly used for promoting blood circulation to remove blood stasis, eliminating carbuncle and removing stasis; pangolin and scorpio which are ministerial drugs are added for mainly enhancing the function of dredging collaterals and removing stasis; indigo naturalis is an assistant drug which has the function of dredging collaterals; radix angelicae which is a supplementary inhibitory drug has the function of warming and removing stasis and can alleviate the cold and cool effect of the whole formula; borneol which is a guide drug is fragrant and disperse and easy to permeate. The medicines are used together for promoting blood circulation to eliminate carbuncle, dredging collaterals and removing stasis, is spicy and migratory and has the function of eliminating swelling and removing stasis. The traditional Chinese medicine disclosed by the invention is simple to prepare, good in absorption effect, remarkable in curative effect, free of side effects and high in safety and can be easily accepted by parents, thereby facilitating quick alleviation of symptoms of the patient.

The present invention relates to compounds of the following general formula (I) or (II) or a pharmaceutically acceptable salt and / or solvate thereof, for use in the prevention and / or the treatment of disorders associated to the inflammation induced by P. acnes, in particular in the prevention and / or the treatment of acne, psoriasis, chronic urticaria, urticaria pigmentosa, cutaneous autoinflammatory diseases, hidradenitis or atopic dermatis.

The present invention relates to flavonoid glycosides isolated from dandelion and capable of preventing and treating Staphylococcus aureus and beta-hemolytic streptococcus infection diseases and their pharmaceutically acceptable salts, their anti-infective medicinal uses, and pharmaceutical compositions containing these compounds. The two novel flavonoid glycoside compounds of the present invention have obvious effects of inhibiting the growth of Staphylococcus aureus and beta-hemolytic streptococcus, and can be expected to be used for the prevention and treatment of boils, pustules and toxic epidermal decomposition caused by the infection of these two. , pneumonia, osteomyelitis, acute myocarditis, endocarditis, meningitis, mastitis, cystitis, pelvic inflammatory disease, urinary tract inflammation, prostatitis, bacteremia, toxic shock syndrome, lymphadenitis, arthritis, pharyngitis , cervicitis, and muscle, skin, urogenital tract, central nervous system abscesses.

The present invention pertains generally to the field of therapeutic compounds. More specifically the present invention pertains to certain N-acyl-{4-[(4-aryl- phenyl)sulfonylmethyl]piperidine} compounds of the following formula (collectively referred to herein as NASMP compounds) that are useful, for example, in the treatment of disorders (e.g., diseases) including, e.g., multiple myeloma, diffuse large B-cell lymphoma, acute myeloid leukemia, eosinophilic leukemia, glioblastoma, melanoma, ovarian cancer, chemotherapy resistant cancer, radiation resistant cancer, inflammatory arthritis, rheumatoid arthritis, psoriatic arthritis, psoriasis, ulcerative colitis, Crohn's disease, systemic lupus erythematosus (SLE), lupus nephritis, asthma, chronic obstructive pulmonary disease (COPD), Hidradenitis suppurativa, autoimmune hepatitis, etc. The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, for example, in therapy.